FDA Approves Phase II Kidney Cancer Therapy Study

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) to undertake a clinical study of the Companys investigational kidney cancer therapy, TLX250 (177Lu-DOTA-girentuximab).